Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results

GlobeNewswire August 9, 2016

Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

GlobeNewswire June 28, 2016

Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28

GlobeNewswire June 27, 2016

Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV

GlobeNewswire June 22, 2016

12 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  June 14, 2016

Mid-Afternoon Market Update: Dow Falls 75 Points; Eleven Biotherapeutics Shares Spike Higher

Benzinga.com  June 13, 2016

Mid-Day Market Update: Smith & Wesson Rises Following Orlando Shootings on Sunday; BioScrip Shares Slide

Benzinga.com  June 13, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  June 13, 2016

Mid-Morning Market Update: Markets Edge Lower; Microsoft To Acquire LinkedIn For $26 Billion

Benzinga.com  June 13, 2016

Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures

GlobeNewswire June 13, 2016

Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference

GlobeNewswire May 3, 2016

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results

GlobeNewswire May 2, 2016

Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

GlobeNewswire April 19, 2016

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus

GlobeNewswire April 15, 2016

Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting

GlobeNewswire April 12, 2016

Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results

GlobeNewswire March 7, 2016

Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference

GlobeNewswire March 1, 2016

Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day

GlobeNewswire January 27, 2016

How it All Plays Out - Free Research Reports on Hill International, Marinus Pharmaceuticals, Ampio Pharmaceuticals and Cutera

Accesswire December 18, 2015

Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures

GlobeNewswire December 16, 2015